Chargement en cours...
Alemtuzumab depletion failure can occur in multiple sclerosis
Alemtuzumab is a lymphocyte‐depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune‐tolerance leading to secondary autoimmunity and marked anti‐drug antibody responses. Although these anti‐drug responses have been reported...
Enregistré dans:
| Publié dans: | Immunology |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5980120/ https://ncbi.nlm.nih.gov/pubmed/29247512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.12879 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|